Suven Pharmaceuticals: June ’22 Results Update
Moneylife Digital Team 07 September 2022
Suven Pharmaceuticals’ (Suven’s) Q1FY22-23 revenue was up by 28% y-o-y (year-on-year) to Rs339 crore, aided by growth in pharma and specialty chemicals CDMO (contract development and manufacturing organisation) segment. Pharma CDMO sales registered a growth of 37% y-o-y to Rs210 crore and specialty CDMO top-line also rose by 38% y-o-y to Rs117 crore. However, formulations segment’s sales...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
SINGLE ARTICLE
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
 
Get access to complete archives
Rs 5000 + GST
 
 
Already a subscriber ? Log in
Free Helpline
Legal Credit
Feedback